Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation

Drug Metabolism and Disposition

Volumn 39, Issue 8, 2011, Pages 1388-1395

  Hosomi, Hiroko ^a   Fukami, Tatsuki ^a   Iwamura, Atsushi ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMIODARONE; CLOZAPINE; CYCLIZINE; CYTOCHROME P450 3A4; DANTROLENE; DESIPRAMINE; DISULFIRAM; FELBAMATE; FLUTAMIDE; ISONIAZID; LABETALOL; LEFLUNOMIDE; MAPROTILINE; NEFAZODONE; NILUTAMIDE; NITROFURANTOIN; PARACETAMOL; ROSIGLITAZONE; SMALL INTERFERING RNA; SULINDAC; TACRINE; TERBINAFINE; TETRAZOLIUM; TOLCAPONE; TRANSCRIPTION FACTOR NRF2; TROGLITAZONE; ZAFIRLUKAST;

ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; DRUG DETOXIFICATION; ENZYME ACTIVITY; GENE CONTROL; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER TOXICITY; METABOLIC ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

BIOLOGICAL ASSAY; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROME P-450 CYP3A; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; ENZYME ACTIVATION; HUMANS; NF-E2-RELATED FACTOR 2; PHARMACEUTICAL PREPARATIONS; SENSITIVITY AND SPECIFICITY;

ADENOVIRIDAE;

EID: 79959486333     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037077     Document Type: Article

References (48)

1. Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, and Ishak KG (1981) Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med 95:588-590. (Pubitemid 12231800)
2. Aoyama T, Korzekwa K, Nagata K, Gillette J, Gelboin HV, and Gonzalez FJ (1990) Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 126:3101-3106. (Pubitemid 20216567)
3. Arellano F and Sacristán JA (1993) Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 27:337-343. (Pubitemid 23086961)
4. Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, Alam J, and Motterlini R (2003) Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 371:887-895. (Pubitemid 36578887)
5. Balson R, Gibson PR, Ames D, and Bhathal PS (1995) Tacrine-induced hepatotoxicity. Tolerability and management. CNS Drugs 4:168-181.
6. Beaune P, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, Leroux JP, and Homberg JC (1987) Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 84:551-555. (Pubitemid 17006233)
7. Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Eugene D, Loeper J, Gauthier JC, Beaune P, and Pompon D (1993) Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther 265:366-372. (Pubitemid 23320983)
8. Boelsterli UA, Ho HK, Zhou S, and Leow KY (2006) Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab 7:715-727. (Pubitemid 44509678)
9. Boelsterli UA and Lim PL (2007) Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol 220:92-107. (Pubitemid 46427861)
10. Chan K, Han XD, and Kan YW (2001) An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci USA 98:4611-4616. (Pubitemid 32295024)
11. Donato MT, Castell JV, and Gómez-Lechón MJ (1995) Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab Dispos 23:553-558.
12. Egnell AC, Houston B, and Boyer S (2003) In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 305:1251-1262. (Pubitemid 36618005)
13. Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, and Pessayre D (1994) Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 269:954-962. (Pubitemid 24204174)
14. Gómez-Lechón MJ, Donato MT, Castell JV, and Jover R (2003) Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 4:292-312. (Pubitemid 36958330)
15. Gómez-Lechón MJ, Donato T, Jover R, Rodriguez C, Ponsoda X, Glaise D, Castell JV, and Guguen-Guillouzo C (2001) Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. Eur J Biochem 268: 1448-1459. (Pubitemid 32231899)
16. Glue P, Banfield CR, Perhach JL, Mather GG, Racha JK, and Levy RH (1997) Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation. Clin Pharmacokinet 33:214-224. (Pubitemid 27399547)
17. Guengerich FP (2008) Cytochrome P450 and chemical toxicology. Chem Res Toxicol 21:70-83.
18. Guengerich FP and MacDonald JS (2007) Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol 20:344-369. (Pubitemid 46548682)
19. Hosomi H, Akai S, Minami K, Yoshikawa Y, Fukami T, Nakajima M, and Yokoi T (2010) An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and γ-glutamylcysteine synthetase knockdown cells. Toxicol in Vitro 24:1032-1038.
20. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, and Lee SD (2003) Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37:924-930.
21. Iverson SL and Uetrecht JP (2001) Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. Chem Res Toxicol 14:175-181. (Pubitemid 32173319)
22. Kalgutkar AS, Vaz AD, Lame ME, Henne KR, Soglia J, Zhao SX, Abramov YA, Lombardo F, Collin C, Hendsch ZS, et al. (2005) Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab Dispos 33:243-253. (Pubitemid 40216592)
23. Klatskin G (1975) Toxic and drug-induced hepatitis, in Diseases of the Liver, 4th ed (Schiff L ed) pp 604-710, JB Lippincott, Philadelphia.
24. Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, Uchida K, and Yamamoto M (2006) Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol 26:221-229.
25. Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, and Silber PM (1999) Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 121:17-35. (Pubitemid 29240667)
26. McCarthy TC, Pollak PT, Hanniman EA, and Sinal CJ (2004) Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-α target gene activation. J Pharmacol Exp Ther 311:864-873. (Pubitemid 39612690)
27. Mizuno K, Katoh M, Okumura H, Nakagawa N, Negishi T, Hashizume T, Nakajima M, and Yokoi T (2009) Metabolic activation of benzodiazepines by CYP3A4. Drug Metab Dispos 37:345-351.
28. Nakajima M, Itoh M, Sakai H, Fukami T, Katoh M, Yamazaki H, Kadlubar FF, Imaoka S, Funae Y, and Yokoi T (2006) CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer 119:2520-2526. (Pubitemid 44691304)
29. Nakamura A, Nakajima M, Higashi E, Yamanaka H, and Yokoi T (2008) Genetic polymorphisms in the 5′-flanking region of human UDP- glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation. Pharmacogenet Genomics 18:709-720.
30. Nguyen T, Sherratt PJ, Nioi P, Yang CS, and Pickett CB (2005) Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap 1. J Biol Chem 280:32485-32492. (Pubitemid 41361861)
31. Nioi P, McMahon M, Itoh K, Yamamoto M, and Hayes JD (2003) Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem J 374:337-348. (Pubitemid 37094093)
32. O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, Gao B, Kaludercic N, Angeline A, Bernardi P, et al. (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80:580-604.
33. Ohbuchi M, Miyata M, Nagai D, Shimada M, Yoshinari K, and Yamazoe Y (2009) Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity. Drug Metab Dispos 37:97-105.
34. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2000) A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303-1310.
35. Osseni RA, Debbasch C, Christen MO, Rat P, and Warnet JM (1999) Tacrine-induced reactive oxygen species in a human liver cell line: the role of anethole dithiolethione as a scavenger. Toxicol In Vitro 13:683-688. (Pubitemid 29354196)
36. Smith KS, Smith PL, Heady TN, Trugman JM, Harman WD, and Macdonald TL (2003) In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem Res Toxicol 16:123-128. (Pubitemid 36245861)
37. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, and Biswal S (2002) Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62:5196-5203. (Pubitemid 35033454)
38. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, and Yokoi T (2004) Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 64:3119-3125. (Pubitemid 38581412)
39. Vignati L, Turlizzi E, Monaci S, Grossi P, Kanter R, and Monshouwer M (2005) An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 216:154-167. (Pubitemid 41712005)
40. Wang Y, Gray JP, Mishin V, Heck DE, Laskin DL, and Laskin JD (2008) Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med 44:1169-1179.
41. Watkins PB (1992) Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 21:511-526.
42. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761. (Pubitemid 36617664)
43. Williams DP, Pirmohamed M, Naisbitt DJ, Maggs JL, and Park BK (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 283:1375-1382. (Pubitemid 28016513)
44. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, and de Graaf D (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105:97-105.
45. Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP, and Yokoi T (1999) Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27:1260-1266.
46. Yoshikawa Y, Hosomi H, Fukami T, Nakajima M, and Yokoi T (2009) Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity. Toxcol In Vitro 23:1179-1187.
47. Yoshitomi S, Ikemoto K, Takahashi J, Miki H, Namba M, and Asahi S (2001) Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol In Vitro 15:245-256. (Pubitemid 32476834)
48. Yun CH, Okerholm RA, and Guengerich FP (1993) Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 21:403-409. (Pubitemid 23154196)